Clinical Study

A081105- Randomized Study Of Erlotinib Vs Observation In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (Nscls)

Posted Date: May 15, 2019

  • Investigator: Christopher Lemmon
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is To assess whether adjuvant therapy with erlotinib will result in improved overall survival over observation for patients with completely resected stage IB-IIIA EGFR mutant NSCLC following complete resection and standard post-operative therapy.


To Be Eligible: Previously Registered To A151216, Must Have Early Stage Nsclc, Age 18 Or Older, Nonpregnant/Nonlactating


Lung Cancer, Nsclc, Cancer, Lung

For More Information:

Uc Cancer Center